<DOC>
	<DOCNO>NCT03038828</DOCNO>
	<brief_summary>Study dose escalation study . Fifteen patient enrol 2 treatment cohort . Five participant ( cohort A ) treat 200IU Multikine daily , 5 days/week 2 week , 2 week , 5 days/week 2 week . If serious adverse event note cohort A patient , ten participant treat cohort B. Cohort B participant treat cohort A participant except dose increase 400IU Multikine per day .</brief_summary>
	<brief_title>Study Leukocyte Interleukin , Injection Treatment Perianal Warts</brief_title>
	<detailed_description>Study dose escalation study determine safety Leukocyte Interleukin , Injection treat men woman perianal wart HIV/HPV co-infected . Fifteen patient enrol 2 treatment cohort . Five participant ( cohort A ) treat 200IU Multikine daily , 5 days/week 2 week , 2 week , treat 5 days/week 2 week . If serious adverse event note cohort A patient , ten ( 10 ) participant treat cohort B. Cohort B participant treat manner cohort A participant except dose increase 400IU Multikine per day .</detailed_description>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>1 . ≥18 year age 2 . Diagnosed perianal condyloma primary clinician 3 . HIVinfected , may antiretroviral therapy . Enrolment subject HAART restrict individual alternative regimen reasonably construct case failure . 4 . Negative reaction intradermal test ciprofloxacin ( fluoroquinolone antibiotic ) 5 . Any CD4 count consider appropriate study 6 . Blood WBC &gt; 2.0x103/mm3 absolute neutrophil count &gt; 500 7 . Blood hemoglobin &gt; 10.0 g/dL 8 . Blood platelet count &gt; 50x103/mm3 9 . Serum total bilirubin &lt; 6.0 mg/dL ( participant take atazanavirbased ARV regimen may elevate total bilirubin generally &lt; 6 ) 10 . Blood aspartate aminotransferase ( AST ) &lt; 100 U/L ( &lt; 2 ULN ) 11 . Blood alanine aminotransferase ( ALT ) &lt; 130 U/L ( &lt; 2 ULN ) 12 . Serum creatinine &lt; 1.5 mg/dL 13 . ECOG performance status &lt; 3 14 . If subject reproductive potential he/she her/his sexual partner MUST willing able utilize highly effective method contraception ( e.g. , birth control pill , barrier method spermicide applicable ) duration study include study followup period . 15 . Subjects must willing refrain anal sex , douche use enema prior schedule Pap smear 1 . Anal cancer ( current history ) 2 . Inability attend study visit 3 . Participation drug study 4 . History asthma 5 . History CHF and/or cardiac support arrhythmia chronic cardiac medication chronic acute cardiac ailment ( e.g. , abnormal EKG Baseline ) 6 . History organ transplantation require chronic administration immune suppressive drug last 6 month 7 . For woman , neither pregnant lactating 8 . In opinion Primary Investigator , subject may able tolerate study treatment regimen 9 . Subjects currently use recently within past 3 month ) treat immunomodulators ( e.g. , Interferonα ) 10 . Subjects active infection include sexually transmit disease ( e.g. , N. gonorrhea , C. trachomatis , H. ducreyi , T. pallidum ) 11 . History allergic reaction fluoroquinolone antibiotic ( e.g. , ciprofloxacin , ofloxacin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>